A Phase II Trial of a TS-1/Cisplatin Based Definitive Chemoradiotherapy for Resectable Esophageal Cancer
- To evaluate response rate in patients with stage IIA-IVA resectable esophageal cancer
treated with chemoradiotherapy comprising S-1, cisplatin, and radiotherapy.
- To evaluate overall survival of these patients.
- To evaluate progression-free survival of these patients.
- To evaluate toxicity in these patients.
- To correlate initial squamous cell carcinoma antigen and C-reactive protein with
response and survival in these patients.
OUTLINE: Patients receive oral S-1 twice weekly, cisplatin IV over 2 hours on day 1, and
undergo radiotherapy 5 days a week in weeks 1 and 2. Treatment repeats every 3 weeks for 2
Tumor tissue samples are collected by esophagoscopy with biopsy and brushings for analysis
of initial squamous cell carcinoma antigen and C-reactive protein correlation with response
After completion of study treatment, patients are followed for 6 months.
Masking: Open Label, Primary Purpose: Treatment
Joo-Hang Kim, MD